BRIEF

on DIAGNOSTIC MEDICAL (EPA:ALDMS)

DMS GROUP 2023 financial results and outlook for 2024

DMS Group, a player in medical imaging systems, revealed a turnover of 42.2 million euros for 2023, up 20% compared to 2022. The group integrated Solutions For Tomorrow in the fourth quarter , contributing 1.7 million euros.

EBITDA stood at 1.7 million euros, down 12% compared to the previous year, affected by the launch of the Platinum Neo table. The acquisition of Solutions For Tomorrow strengthened DMS's offering in mobile radiology, present in 35 countries. The group also absorbed delivery delays in the first quarter of 2024 due to a cyberattack, with a quarterly turnover of 9.9 million euros.

For 2024, DMS is targeting growth reinforced by the optimization of production costs and by its investments in research and development which amount to 2.2 million euros. The consolidation of its operational structure in 2023 helps it maintain its roadmap towards increased profitability.

R. P.

Copyright © 2024 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.

Click here to consult the press release on which this article is based

See all DIAGNOSTIC MEDICAL news